Fertissimo TCL Analyzer is an innovative, noninvasive embryo selection system for the IVF market, offering up to 20% increase in successful IVF pregnancies. Effective embryo viability assessment significantly improves success rate and reduces the risk of multiple births. Successful clinical trials were performed in Israel and in Europe (Spain). New generation of the product will soon start extensive clinical validation and will be launched in 2020. CE Mark is expected in two months. Business model is pay-per-test using the disposable and software control, while the devices will be sold with nominal price.
Accurate,scientifically based, NON-INVASIVE solution to the embryo selection application - the "holy grail" of the IVF process.- Low cost device, minimal initial investment for the users- Very friendly,easy-to-use system- Optional oocyte quality testing- Examining the patient's probability for pregnancy - not just on embryo base- Testing cryopreserved - thawed embryos. The device can also be used for additional applications such as: Risk stratification for Heart Failure patients, Diagnosis and treatment monitoring of AMD, early diagnosis of Parkinson and Alzheimer's, assessment of damage in TBI - Traumatic Brain injury. We base our solution on using oxidative stress as a novel efficient biomarker. The potential market is each and every IVF clinic in the world. There are more than 3000 clinics world wide and over 2 Millions IVF procedures (Cycles) every year with expected growth of 5-7%. The market size of embryo selection is 500M$. The product is needed world wide in every IVF clinic. Improving success rate in the procedure is very important considering high cost, pain and stress to the patients and couples in general.

Carmel Diagnostics

Tzali Cnaani

This department is responsible for setting the overall vision and strategic direction of the organization.

Carmel Diagnostics

Org chart

Teams

Executive Leadership

Offices